Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Effect of Pentoxifylline on Carbohydrate Metabolism in Type II Diabetics

Effect of Pentoxifylline on Carbohydrate Metabolism in Type II Diabetics Abstract To the Editor. — During the past years we have seen two patients with advanced type II diabetes mellitus (non— insulin-dependent diabetes mellitus), macroangiopathy and microangiopathy, and intermittent claudication. They responded poorly to treatment with sulfonylureas and were given insulin. Their metabolic balance remained inadequate. Because of intermittent claudication, they were given 400 mg of pentoxifylline (Trental) orally three times a day. Without changing the insulin dose, adequate balance was obtained in carbohydrate metabolism as seen in blood and urine glucose levels and glycosylated hemoglobin A1c levels. After 2 months of treatment, there was also improvement in walking distance. One of the patients continued to receive the "second-generation" sulfonylurea preparation, glyburide (DiaBeta), throughout this course of treatment. It is assumed that the mechanism of action of sulfonylureas is based on (1) increased insulin secretion by the beta cells of the pancreas, (2) suppression of glucagon and hepatic glucose production, References 1. Ambrus JL. Microvascular changes in diabetes . In: Kerstein M, ed. Diabetes and Vascular Disease . Philadelphia, Pa: JB Lippincott Co. In press. 2. Gastpar H, Ambrus JL, Ambrus CM, Spavento P, Weber FJ, Thurber LE. Study of platelet aggregation in vivo, III: effect of pentoxifylline . J Med . 1977;8:191-197. 3. Ambrus JL, Ambrus CM, Taheri SA, et al. Red cell flexibility and platelet aggregation in patients with chronic obstructive vascular disease (COAD) and study of therapeutic approaches . Angiology . 1984;35:418-426.Crossref 4. Ambrus CM, Ambrus JL, Gastpar H, et al. The role of fibrinolysis in the therapy of peripheral vascular disease . Angiology . 1984;35:436-442.Crossref 5. Masiwezkij AH, Stoilov LD, Kukashina TV, Tirkina TN, Titova SI. The use of pentoxifylline in diabetes mellitus . Pharmatherapeutica . 1978; 2:105-108. 6. Solerte SB, Ferrari E. Diabetic retinal vascular complications and erythrocyte filterability: results of a 2-year follow-up study with pentoxifylline . Pharmatherapeutica . 1985;4:341-350. 7. Schubotz R. Double-blind trial of pentoxifylline in diabetics with peripheral vascular disorders . Pharmatherapeutica . 1976;1:172-179. 8. Raptis S, Mitrakou A, Hadjidakis D, et al. Twenty-four hour blood glucose pattern in type I and type II diabetics after oral treatment with pentoxifylline as assessed by artificial endocrine pancreas . Acta Diabetol Lat . 1987;24:181-192.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Internal Medicine American Medical Association

Effect of Pentoxifylline on Carbohydrate Metabolism in Type II Diabetics

Effect of Pentoxifylline on Carbohydrate Metabolism in Type II Diabetics

Abstract

Abstract To the Editor. — During the past years we have seen two patients with advanced type II diabetes mellitus (non— insulin-dependent diabetes mellitus), macroangiopathy and microangiopathy, and intermittent claudication. They responded poorly to treatment with sulfonylureas and were given insulin. Their metabolic balance remained inadequate. Because of intermittent claudication, they were given 400 mg of pentoxifylline (Trental) orally three times a day. Without changing the...
Loading next page...
 
/lp/american-medical-association/effect-of-pentoxifylline-on-carbohydrate-metabolism-in-type-ii-4IxRy7zQaC
Publisher
American Medical Association
Copyright
Copyright © 1990 American Medical Association. All Rights Reserved.
ISSN
0003-9926
eISSN
1538-3679
DOI
10.1001/archinte.1990.00390160161056
Publisher site
See Article on Publisher Site

Abstract

Abstract To the Editor. — During the past years we have seen two patients with advanced type II diabetes mellitus (non— insulin-dependent diabetes mellitus), macroangiopathy and microangiopathy, and intermittent claudication. They responded poorly to treatment with sulfonylureas and were given insulin. Their metabolic balance remained inadequate. Because of intermittent claudication, they were given 400 mg of pentoxifylline (Trental) orally three times a day. Without changing the insulin dose, adequate balance was obtained in carbohydrate metabolism as seen in blood and urine glucose levels and glycosylated hemoglobin A1c levels. After 2 months of treatment, there was also improvement in walking distance. One of the patients continued to receive the "second-generation" sulfonylurea preparation, glyburide (DiaBeta), throughout this course of treatment. It is assumed that the mechanism of action of sulfonylureas is based on (1) increased insulin secretion by the beta cells of the pancreas, (2) suppression of glucagon and hepatic glucose production, References 1. Ambrus JL. Microvascular changes in diabetes . In: Kerstein M, ed. Diabetes and Vascular Disease . Philadelphia, Pa: JB Lippincott Co. In press. 2. Gastpar H, Ambrus JL, Ambrus CM, Spavento P, Weber FJ, Thurber LE. Study of platelet aggregation in vivo, III: effect of pentoxifylline . J Med . 1977;8:191-197. 3. Ambrus JL, Ambrus CM, Taheri SA, et al. Red cell flexibility and platelet aggregation in patients with chronic obstructive vascular disease (COAD) and study of therapeutic approaches . Angiology . 1984;35:418-426.Crossref 4. Ambrus CM, Ambrus JL, Gastpar H, et al. The role of fibrinolysis in the therapy of peripheral vascular disease . Angiology . 1984;35:436-442.Crossref 5. Masiwezkij AH, Stoilov LD, Kukashina TV, Tirkina TN, Titova SI. The use of pentoxifylline in diabetes mellitus . Pharmatherapeutica . 1978; 2:105-108. 6. Solerte SB, Ferrari E. Diabetic retinal vascular complications and erythrocyte filterability: results of a 2-year follow-up study with pentoxifylline . Pharmatherapeutica . 1985;4:341-350. 7. Schubotz R. Double-blind trial of pentoxifylline in diabetics with peripheral vascular disorders . Pharmatherapeutica . 1976;1:172-179. 8. Raptis S, Mitrakou A, Hadjidakis D, et al. Twenty-four hour blood glucose pattern in type I and type II diabetics after oral treatment with pentoxifylline as assessed by artificial endocrine pancreas . Acta Diabetol Lat . 1987;24:181-192.Crossref

Journal

Archives of Internal MedicineAmerican Medical Association

Published: Apr 1, 1990

References